Drug Trial Radar · NCT06458595
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Jun 28, 2024
Primary completion
Mar 31, 2026
Study completion Dec 28, 2026
Sponsor
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.
Conditions
- Age-related Macular Degeneration
Interventions
KH658Drug
KH658 Ophthalmic Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tolerability and safety of KH658 in different dose levelsTime frame: Week 4, Week 26
- Change in BCVA letterTime frame: Week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University General Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.